Combined dabrafenib and trametinib (CombiDT) is an approved therapy for advanced BRAFV600E/K-mutant melanoma patients. This study shows that pyrexia is frequent and recurrent with CombiDT, but is not associated with baseline characteristics or drug efficacy. The etiology is unclear but may involve drug exposure. This requires further research, as do strategies to prevent recurrent pyrexia.
ASJC Scopus subject areas